Results 101 to 110 of about 13,011 (272)

A Solid Ultra Fine Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) of Deferasirox for Improved Solubility: Optimization, Characterization, and In Vitro Cytotoxicity Studies

open access: yesPharmaceuticals, 2020
The research work was designed to develop a solid self-nanoemulsifying drug delivery system (S-SNEDDS) of deferasirox (DFX). According to the solubility studies of DFX in different components, Peceol, Kolliphor EL, and Transcutol were selected as ...
Alaa Alghananim   +5 more
semanticscholar   +1 more source

Overcoming BET‐inhibitor JQ1 resistance in aggressive non‐small cell lung cancer by inducing ferroptosis via inhibition of the BRD2–FTH1 axis

open access: yesThe FEBS Journal, Volume 292, Issue 23, Page 6345-6364, December 2025.
Recent studies emphasize alternative functions of FTH1 relevant for nuclear processes, such as transcriptional regulation. This study shows a novel FTH1/BRD2 association in non‐small cell lung carcinoma (NSCLC). This nuclear interaction affects BRD2 protein stability in aggressive NSCLC cells.
Stefania Scicchitano   +9 more
wiley   +1 more source

Corrigendum

open access: yesClinicoEconomics and Outcomes Research, 2011
York Zoellner1, Maria-Magdalena Balp2, Andrea Gili Marco21Hamburg University of Applied Sciences, Hamburg, Germany; 2Novartis Pharma AG, Basel, SwitzerlandThe role of galenic innovation in improving treatment compliance and persistence: three case ...
Zoellner Y, Balp MM, Gili Marco A
doaj  

The iron chelator Deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability

open access: yesScientific Reports, 2020
The iron chelator Deferasirox (DFX) causes severe toxicity in patients for reasons that were previously unexplained. Here, using the kidney as a clinically relevant in vivo model for toxicity together with a broad range of experimental techniques ...
E. M. Gottwald   +15 more
semanticscholar   +1 more source

Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving Food and Drug Administration accelerated approval [PDF]

open access: yes, 2017
Context: Therapeutic agents treating serious conditions are eligible for Food and Drug Administration (FDA) accelerated approval. The clinical evidence accrued on agents receiving accelerated approval has not been systematically evaluated.
Gupta, Radhika   +3 more
core   +1 more source

A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications

open access: yesMolecular Oncology, Volume 19, Issue 11, Page 3003-3022, November 2025.
Hypoxia reshapes tumour redox landscapes by altering compartmental ROS production (mitochondria, NOX, ER, peroxisomes). Accurate interpretation requires oxygen‐contextualised measurement (live biosensors, chemical probes, EPR, LC–MS) and awareness of artefacts (reoxygenation, probe specificity).
Lina Hacker   +3 more
wiley   +1 more source

Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox : A Case Report

open access: yesJournal of Microbiology and Infectious Diseases, 2016
In this paper, we present a 69 years old diabetic patient with mucormycosis who was succesfully treated with liposomal amphotericin B (LAMB), posaconazole and deferasirox despite having no adequate surgery.
Uğur Onal   +6 more
doaj   +1 more source

Effect of mercury vapor inhalation on rat ovary: stereology and histopathology [PDF]

open access: yes, 2016
AimMercury, an environmental contaminant, is a risk factor for health in whole living organisms. In this study, we investigated whether mercury vapor (HgO) inhalation has an effect on rat ovary.
Akgul, Hayati Murat   +6 more
core   +1 more source

Intelligent Theranostic Systems Enabled by Aggregation‐Induced Emission in Precision Medicine

open access: yesAggregate, Volume 6, Issue 11, November 2025.
Aggregation‐induced emission (AIE) luminogens are driving a new generation of intelligent theranostic systems that integrate high‐fidelity imaging and multifunctional therapy. This review highlights how AIEgens, through restriction of intramolecular motion (RIM), enable deep‐tissue NIR‐II imaging, ultrasensitive biosensing, CRISPR‐assisted gene ...
Qinqin Huang   +7 more
wiley   +1 more source

The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR Β-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2020
Background: The four most commonly used chelation regimens for β-thalassemia major patients in China are a combination therapy of deferoxamine and deferiprone (DFO+DFP), deferoxamine(DFO) monotherapy, deferiprone(DFP) monotherapy and deferasirox(DFX ...
Jialian Li
doaj   +1 more source

Home - About - Disclaimer - Privacy